不同剂量瑞舒伐他汀钙片治疗冠状动脉粥样硬化的效果及安全性

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the efficacy and safety of different doses of Rosuvastatin Calcium Tablets in the treatment of coronary atherosclerosis(CA).Methods A total of 86 CA patients admitted to Zoucheng People′s Hospital from July 2018 to July 2020 were selected as the research objects,and were divided into the control group(43 cases)and the observation group(43 cases)according to the random number table method.Both groups were treated with Rosuvastatin,the control group was orally administered 10 mg/d,and the observation group was orally administered 20 mg/d.Both continued medication for 3 months.The blood lipid levels,changes in plaque,the degree of lumen stenosis,and the safety of medication were compared between the two groups.Results There was no significant difference in blood lipid levels between the two groups before treatment(P>0.05);After treatment,triacylglycerol(TG),total cholesterol(TC),and low-density lipoprotein cholesterol(LDL-C)were lower than before treatment,and high-density lipoprotein cholesterol(HDL-C)was higher than before treatment,the differences were statistically significant(P＜0.05).There were no statistically significant differences of plaque changes and the degree of lumen stenosis between the two groups before treatment(P>0.05).The maximum area of the plaque cross section and the degree of lumen stenosis after treatment were less than before treatment,and the differences were statistically significant(P＜0.05).The largest cross-sectional area of the plaque and the degree of lumen stenosis in the observation group after treatment were smaller than those in the control group,the differences were statistically significant(P＜0.05).There was no statistically significant difference in total adverse reactions between the two groups(P>0.05).Conclusion High-dose Rosuvastatin has a better lipid-lowering effect in the treatment of CA,which is beneficial to reduce plaque and reduce coronary stenosis without increasing the risk of adverse reactions.

Key words： Coronary atherosclerosis Rosuvastatin Different doses Blood lipid level Safety

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Ting

Cite this article:

WANG Ting. Effect and safety of different doses of Rosuvastatin Calcium Tablets in the treatment of coronary atherosclerosis[J]. 中国当代医药, 2021, 28(25): 87-90.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I25/87

[1]	王建龙，王志坚，史东梅，等.联合药物治疗在冠状动脉粥样硬化患者治疗过程中的应用状况及疗效观察[J].心肺血管病杂志，2018，37（4）：303-306.
[2]	吴学正，吴小燕，陈卫卫，等.阿托伐他汀钙片联合依折麦布片治疗冠状动脉粥样硬化的临床研究[J].中国临床药理学杂志，2018，34（4）：406-409.
[3]	姚立军，陈弹.瑞舒伐他汀与阿托伐他汀对冠心病患者血脂、动脉粥样硬化程度和血管内皮舒张功能的疗效比较[J].中国药房，2017，28（35）：4963-4966.
[4]	范群雄，赵继先，张焕鑫，等.不同剂量瑞舒伐他汀对急性冠状动脉综合征介入术后血脂、炎症因子及心功能影响[J].临床误诊误治，2018，31（3）：73-76.
[5]	中国医师协会心血管内科医师分会，《中华内科杂志》编辑委员会.心血管疾病一级预防中国专家共识[J].中华内科杂志，2010，49（2）：174-185.
[6]	瓦哈甫·马木提，陆荣荣，阿布都乃孜尔·肉孜，等.冠状动脉粥样硬化斑块特性的早期识别及药物干预对血清学指标的影响[J].中国医药，2019，14（2）：175-178.
[7]	刘元媛，李伟.冠状动脉粥样硬化性心脏病高危患者胆固醇合成吸收水平的相关性及其对他汀类药物的反应性研究[J].陕西医学杂志，2018，47（9）：1154-1157.
[8]	刘杰，欧国春，曾静，等.不同强度他汀类药物对中国人群冠状动脉粥样硬化性心脏病疗效及安全性的系统评价[J].国际心血管病杂志，2018，45（2）：117-122.
[9]	董少元，屈艳玲.瑞舒伐他汀与阿托伐他汀治疗冠状动脉斑块疗效及调脂作用观察[J].中国药物与临床，2018，18（12）：2189-2190.
[10]	陈少源，陈菲，黄凤琴，等.瑞舒伐他汀对急性冠状动脉综合征患者Legumain 蛋白表达的影响[J].岭南心血管病杂志，2017，23（1）：27-30，39.
[11]	赵晓静，刘霄岩，刘雪，等.硫酸氢氯吡格雷联合瑞舒伐他汀对老年冠状动脉粥样硬化性心脏病患者生长分化因子15 及炎症因子水平的影响[J].中国医药，2019，14（6）：811-814.
[12]	卢炜，杜超，王立君，等.瑞舒伐他汀对冠心病合并中心动脉压升高病人颈动脉粥样硬化及ox-LDL、LOX-1、Vaspin 水平的影响[J].中西医结合心脑血管病杂志，2018，16（19）：2908-2910.
[13]	李立卓，郑梅，李伟聪，等.法舒地尔联合不同剂量瑞舒伐他汀对冠状动脉慢血流的影响[J].中国全科医学，2019，22（34）：4251-4255.
[14]	赵圣吉，刘超权，郑伟民.瑞舒伐他汀钙片治疗冠状动脉粥样硬化的临床研究[J].中国临床药理学杂志，2019，35（15）：1552-1555.
[15]	贾媛媛，赵殿儒，田田，等.不同剂量瑞舒伐他汀治疗对急性冠状动脉综合征患者体内炎性因子水平的影响[J].解放军医药杂志，2020，32（8）：32-35.
[16]	邓琴.瑞舒伐他汀对急性冠脉综合征患者颈动脉斑块及炎症因子的影响[J].中国医药科学，2020，（18）：88-90.